DANVERS, Mass.--(BUSINESS WIRE)--Vaso Active Pharmaceuticals, Inc. (the “Company”) (VAPH.ob) announced today that it has made the strategic decision to voluntarily suspend filing of its reports under the Securities Exchange Act of 1934 (the “Act”). Although the Company has not been required to make filings under the Act since 2007, it has until now remained a voluntary filer. At the present time, management has determined that it is in the best interest of the Company and its shareholders to eliminate the costs associated with those filings. This decision was made by the Company as part of its strategy to prevent any unnecessary resource allocation in order to allow the Company to preserve and maximize its longevity in pursuing its case for alleged negligence committed by the Company’s former law firm, Robinson Cole. The case is currently pending in the Suffolk Superior Court in Boston Massachusetts.
